The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have issued a joint statement confirming that medicines which are highly similar to another reference medicine (known as biosimilars) that have been approved in the European Union are interchangeable with their reference medicine or with an equivalent biosimilar.
“Interchangeable” in this context means that the substitution of an approved reference drug with a biosimilar causes no change in clinical effect...